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In many cancer types, MYC proteins are known to be master regulators of the RNA-producing machinery. Neuroblastoma is a
tumor of early childhood characterized by heterogeneous clinical courses. Amplification of the MYCN oncogene is a marker of
poor patient outcome in this disease. Here, we investigated the MYCN-driven transcriptome of 20 primary neuroblastomas
with and without MYCN amplification using next-generation RNA sequencing and compared the results to those from an
in vitro cell model for inducible MYCN (SH-EP MYCN-ER). Transcriptome sequencing produced 30–90 million mappable reads
for each dataset. The most abundant RNA species was mRNA, but snoRNAs, pseudogenes and processed transcripts were also
recovered. A total of 223 genes were significantly differentially expressed between MYCN-amplified and single-copy tumors.
Of those genes associated with MYCN both in vitro and in vivo, 32% of MYCN upregulated and 37% of MYCN downregulated
genes were verified either as previously identified MYCN targets or as having MYCN-binding motifs. Pathway analyses
suggested transcriptomal upregulation of mTOR-related genes by MYCN. MYCN-driven neuroblastomas in mice displayed
activation of the mTOR pathway on the protein level and activation of MYCN in SH-EP MYCN-ER cells resulted in high
sensitivity toward mTOR inhibition in vitro. We conclude that next-generation RNA sequencing allows for the identification of
MYCN regulated transcripts in neuroblastoma. As our results suggest MYCN involvement in mTOR pathway activation on the
transcriptional level, mTOR inhibitors should be further evaluated for the treatment of MYCN-amplified neuroblastoma.
Neuroblastoma (NB) is a cancer of childhood presenting
with extreme courses: while aggressive NB still poses a chal-
lenge to clinicians and recurrent disease renders an infaust
prognosis despite multimodal therapy,1 intermediate-risk
patients with favorable tumor biology can be successfully
treated with a less intensive treatment.2 Moreover, benign
neuroblastic tumors can be cured by surgery combined with
a ‘‘wait-and-see’’ strategy.3 Many efforts have been under-
taken to identify risk factors for aggressive neuroblastoma,
but amplification of the MYCN oncogene is still the most
powerful single predictor of adverse outcome of NB.4 MYCN
amplification is observed in about 20% of all NB patients and
is usually associated with fatal outcome of the disease.5 As
MYCN is a transcription factor, thus not representing an
ideal druggable target, molecular analyses of this subgroup of
NB promises to result not only in a better understanding of
MYCN driven tumor biology but also in novel treatment
options for this most aggressive tumor subtype.
With the onset of affordable next-generation sequencing
(NGS) technologies, it can be anticipated that underlying
gene mutations for every tumor will be identified within the
next few years. For NB, first reports on the mutational spec-
trum of the disease have been recently published,6 stressing
the importance of MYCN, chromosomal stability and muta-
tions in neuritogenesis genes for neuroblastoma development.
In neuroblastoma, a genetic association with the onset of the
disease has only been found for a small fraction of all cases.
Activating mutations in the coding gene for anaplastic
lymphoma kinase (ALK) have been described in about
eight percent of all NB patients,7–11 while mutations in the
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PHOX2B gene, which is also associated with Hirschsprung
disease, are even less frequent (1–2%12,13). Therefore, the vast
majority of neuroblastomas are sporadic cases with a hetero-
geneous mutational spectrum. In the light of endeavors to
treat patients according to their individual risk profile, these
heterogeneity could imply that risk factors such as MYCN
amplification or loss of chromosome 11q14,15 will still have
an impact on the choice of individualized treatment. More-
over, the impact of the ‘‘mutanome’’ as the sum of all can-
cer-associated genetic changes on transcriptomal alterations
remains to be explored.
We have previously reported on tumor-associated changes in
the small RNA transcriptome of primary neuroblastoma thus
describing the entire spectrum of NB-associated miRNAs.16 The
oncogenic or tumor-suppressive functions of these miRNAs
could be verified by independent methods and experiments17,18
exemplifying that the results from next-generation sequencing
can be meaningfully exploited for functional studies.
Here, we focused on the coding transcriptome of primary
NB by comparing absolute RNA expression levels in tumor
samples from patients with and without MYCN amplification
using next-generation RNA sequencing. To identify direct
MYCN targets we also included an NB cell line with induci-
ble induction of MYCN in the sequencing pipeline. The
intersection of regulated genes between the in vivo and the in
vitro samples was anticipated to include genes, whose expres-
sion is tightly linked or directly regulated by MYCN. With
this information at hand it was expected that MYCN gene
regulatory networks as well as potential targets for MYCN-
driven NB could be identified.
Material and Methods
Cell culture and in vitro analyses
Cultivation of human neuroblastoma cells SH-EP, SH-EP
MYCN-ER and WAC2 was performed as previously
described.19 SH-EP is a MYCN null neuroblastoma cell line
and genetically identical to SH-SY5Y but displaying an epi-
thelium-like phenotype.20 WAC2 is a subclone of SH-EP
engineered to stably overexpress MYCN.21 Activation of
MYCN in SH-EP MYCN-ER was achieved using 4-hydroxy
tamoxifen and confirmed after 72 hr by detecting transcrip-
tional induction of the MYCN-target gene, ODC-1, as
described.19 Cell viability following treatment with BEZ-235
(Axon Medchem, Groningen, The Netherlands) was meas-
ured using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazoliumbromide) as previously described.22
RNA preparation for next generation sequencing
NB patients included in this study were from German trials
NB 97 or 2004, respectively. Representative areas of histologi-
cally confirmed, snap-frozen NB were cut on dry ice. No pre-
selection for tumor cell fraction or microenvironment was
performed. Total RNA extraction of NB tumor samples and
cell lines described above was performed by silica gel-based
membrane purification methods (RNeasy Mini kit or Micro-
RNeasy kit, Qiagen, Hilden, Germany) according to the man-
ufacturer’s instructions. Depletion of ribosomal RNAs was
achieved using the RiboMinus Human Transcriptome Kit
(Invitrogen, Carlsbad, CA) according to the manufacturer’s
instructions. RNA quality as well as rRNA depletion effi-
ciency was controlled by capillary gel electrophoresis using
the Bioanalyser 2100 (RNA nano kits, Agilent).
Library generation and transcriptome sequencing
Library preparation was performed as previously described.23
Of the depleted rRNA, 50–500 ng was used as input for the
whole transcriptome analysis kit (Applied Biosystems, Carls-
bad, CA). Library preparation was performed according to the
manufacturer’s protocol. Sequencing was performed using the
SOLiD ‘‘Top Paired End Seq DNA Frag Kit MM 50/35 v4’’
(Applied Biosystems, Carlsbad, CA) on the SOLiD V4 plat-
form. In total 24 libraries were generated and sequenced.
Sequence processing and mapping
SOLiD reads were mapped to the Human Genome RefSeq
Hg19 using Bioscope v1.21. A clearzone of 5.0 and mismatch
penalty of 2.0 were set, and a repetitive mapping was per-
formed using the following settings: 38.3.0, 25.2.0 (anchor-
Length.mismatchAllowed.anchorStart). See the ‘‘Bioscope
Userguide’’ for a more detailed description of the Bioscope
mapping algorithm. For ambiguous mappings, only the align-
ment with best mapping quality was considered. Based on
the ENSEMBL Hg19 annotation (rev. 63), per gene expres-
sion values were set as the maximum coverage of the exonic
gene regions.
Normalization
Gene expressions were normalized to allow comparison
across datasets. A qq-scale normalization as described in Ref.
16 was performed separately for the tumor samples and the
in vitro datasets. Quantile–quantile (qq) plots of the distribu-
tion of gene expression values of each dataset against one
arbitrarily chosen reference dataset were compared. By
What’s new?
In neuroblastoma, amplification of the MYCN oncogene is associated with a poor prognosis. Now that next-generation
sequencing technologies are becoming more affordable, it may soon be possible to identify the mutations underlying
individual tumors, and to use that information to develop individualised treatment strategies. In this study, the authors used
‘‘RNA deep sequencing’’ to examine the MYCN-driven transcriptomes of a number of neuroblastomas. Their results suggest
that mTOR inhibitors should be further evaluated for the treatment of MYCN-amplified neuroblastoma.
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considering only the 75–95% quantiles, robustness against
less abundant genes and outliers was ensured. With the scal-
ing factor given by the median of differences between these
quantiles, a purely linear transformation was performed.16
Statistical testing and cluster analysis
Statistical analysis and clustering of gene expressions was per-
formed using R 2.14 (http://www.r-project.org). Genes were
tested for differential expression using MYCN status (ampli-
fied vs. normal) or survival (see Supporting Information Ta-
ble 1 for patient characteristics) as variables. For each gene,
the fold change was computed as the ratio of the mean gene
expressions of the classes, while fold changes between 1 and
0 were replaced by the negative of their inverse. In the tumor
datasets, genes with a p value < 0.05 and an absolute fold
change of at least 1.5 were considered to be significantly dif-
ferentially expressed. The false discovery rate (FDR) was cal-
culated using Benjamini–Hochberg multiple testing correc-
tion using the R library ‘‘multtest.’’24,25 Hierarchical
clustering was performed based on Canberra distances.16
In silico verification of potential MYCN targets
A list of potential MYCN targets was obtained by selecting
genes that were significantly differentially expressed using
MNA classification in the tumor and exhibited an absolute
fold change of at least 1.5 in the in vitro datasets. Potential
targets were verified using existing databases (MYC target
gene database, http://www.myccancergene.org,26 and the
MYCNot Database [http://medgen.ugent.be/MYCNot]). Fur-
ther, the MYCN binding motif E-Box (CACGTG), together
with its isoforms (CATGTG, CATTTG, CATCTG,
CAACTG) reported by Ref. 27 was tested for significant over-
representation (p  0.05) in the promoter regions of the
genes. Therefore, each motif was tested in a 1,000 base region
upstream of the first exon of each gene using the sequence
alignment tool MosDi (http://code.google.com/p/mosdi/,28).
Confirmation of mTOR pathway activation in tumors from
TH-MYCN mice
TH-MYCN mice were housed in the central animal facility
of the University Hospital Essen. These mice developed neu-
roblastoma at a frequency comparable to published data.29
Total protein was isolated from tumors and normal livers of
three tumor-bearing animals. Western blot analysis was per-
formed to detect total Akt, phospho-Akt, total p70S6K and
phospho-p70S6K to evaluate Akt/mTOR pathway activation.
All primary antibodies were obtained from Cell Signaling
(Beverly, MA).
Results
Following RNA isolation and rRNA depletion, transcriptomes
from 20 primary NB with and without MYCN amplification
and a NB cell line with and without induction of MYCN
(SH-EP MYCN-ER) were analyzed by NGS using paired-end
sequencing on a SOLiD4 sequencer (Applied Biosystems).
Patient characteristics are listed in Supporting Information
Table 1. Mapping against the human genome RefSeq Hg19
was performed using BioScope (see Methods). On average,
31.615.883 reads for each tumor, and 89.689.520 reads for
each in vitro dataset could be mapped to the reference ge-
nome. The most abundant class of RNA species were protein
coding mRNAs, followed by snoRNAs, pseudogenes and
processed transcripts, which are noncoding transcripts with-
out an open reading frame (Fig. 1). The distribution of RNA
species underscores both the efficiency for rRNA depletion
and mRNA enrichment in our samples.
All transcripts were mapped to the ENSEMBL Hg19
annotation containing 53,717 features including coding genes.
Of those, 8030 coding genes were found to have absolute
expression counts >10 in at least five samples. To obtain
comparable expression values, a qq-scale normalization
Figure 1. Distribution of RNA species for the samples sequenced
by NGS. Note that the predominant form is mRNA (light blue), but
that also lincRNAs, snoRNAs and snRNAs were readily detectable,
although at lower levels. Immunoglobulin pseudogenes and
miRNAs (subsumed in white) are only present in minor amounts
due to the size selection and depletion strategy. ‘‘MYCNsc’’ and
‘‘MNA’’ refers to samples from MYCN single-copy or MYCN-
amplified patients, respectively. ‘‘SH-EP MYCN-ER’’ refers to
samples from the SH-EP MYCN-ER cell line before (‘‘-’’) and after
induction of MYCN (‘‘þ’’) by 4-OHT. Transcriptomes of cell lines
were analyzed in duplicate from independent biological samples.
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among all tumor datasets was performed (see methods, Figs.
2a and 2b) and expression values were then calculated for all
tumor datasets (see methods). We first focused on differential
expression analysis to find gene expression patterns as well as
individual genes with significant expression differences
between MYCN-amplified and MYCN single copy tumors or
expression patterns associated with survival. Only genes with
an absolute expression count of at least 10 in at least five tu-
mor datasets were selected for these analyses. Based on our
filter criteria, 945 and 727 genes were used for classification
according to MYCN status or survival, respectively, and p
values for differential expression were calculated. A total of
223 genes were significantly differentially expressed between
patients with MYCN amplification and patients with normal
MYCN status. For patients surviving their disease for >3
years without an event, 211 genes were found to be signifi-
cantly different when compared to the patients succumbing
to their disease. To address the problem of multiple testing,
we plotted the distribution of p values to evaluate if low
p values were over-represented between the different groups.
Indeed, there is an enrichment of low p values when gene
expression was compared for patients with or without MYCN
amplification and those surviving the disease to those who
succumbed (Figs. 2c and 2d). This finding implies that there
are true transcriptomal differences between these groups.
Looking at the most differentially expressed transcripts con-
sidering MYCN amplification (Fig. 3a) or survival (Fig. 3b)
both upregulation and downregulation of candidate MYCN
targets could be detected. Mostly, we observed regulation of
protein coding mRNAs, but also differential expression of
snoRNAs including SNORA71C and SNORD116 was
observed. An unsupervized hierarchical clustering using all
significantly differentially expressed genes resulted in a per-
fect separation between MYCN amplified and MYCN normal
patients (Fig. 3c). When trying to separate patients according
to survival based on the list of significantly differentially
expressed transcripts, we noticed that there was one misclas-
sification (Fig. 3d). Taken together, the principled differences
between the transcriptomes of aggressive and less aggressive
neuroblastomas allowed for the separation of these clinically
divergent groups. Genes and transcripts with significant dif-
ferential expression dependent on the MYCN amplification
status are candidate direct or indirect MYCN targets. To
obtain insights into a direct MYC regulation of the tran-
scripts that were identified in the primary tumors, a well-
established model system of inducible MYCN function in a
neuroblastoma cell line, SH-EP MYCN-ER, was used. In this
model system, MYCN is expressed in a cell line without
endogenous MYCN as a fusion gene with the estrogen-
responsive domain of the ER receptor. MYCN activation can
only be induced in the presence of 4-hydroxy-tamoxifen
causing a nuclear translocation of the MYCN-ER fusion
Figure 2. Effects of normalization on transcriptome comparability. A qq-normalization was performed separately for in vivo (a) and in vitro
(b) samples, using the quantiles between 75 and 95% to ensure robustness. Histogram of uncorrected p values after testing equality of
expression count means for each RNA between MYCN-amplified vs. MYCN single copy tumors (c) or patients who died from their disease
vs. patients who survived (d). Distribution of P-values is expected to be uniformly distributed across the unit interval (blue line), when data
with equal means were compared. Here, p values <0.05 (red line) are enriched, indicating significant differences between the groups
analyzed.
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protein. The transcriptome of SH-EP MYCN-ER cells with or
without induction of functional MYCN was analyzed by
RNA sequencing as described for the primary tumors and
differentially expressed transcripts in the presence or absence
of functional MYCN were identified accordingly. The list of
transcripts associated with MYCN amplification in vivo and
transcripts induced by MYCN in vitro were then compared
to narrow down the candidate genes directly targeted by
MYCN. For this purpose, we first omitted all genes that had
a fold change (either up or down) of <1.5 in vitro. Second,
we kept only those genes, for which the sign of the fold
change (i.e., the direction of regulation) was the same in
tumors and in vitro. Application of these filter criteria
resulted in 25 genes that were upregulated (positive fold
change) and 19 genes that were downregulated (negative fold
change) upon MYCN induction in vitro (Figs. 4a and Sup-
porting Information S2) and MYCN amplification (Figs. 4b
and Supporting Information S2). Among the upregulated
genes, we found three known MYCN targets as described in
publicly available databases (see Methods). Interestingly, we
also identified 7 MYCN target genes to be downregulated.
Homology searches identified an E-Box binding motif, which
is the MYCN transcription factor binding site, in the pro-
moter region of five upregulated genes and one
Figure 3. Significantly different expressed genes in tumor samples grouped by MYCN status (a) or survival (b). The 40 genes with the lowest
uncorrected p values are presented as strip chart of normalized read count. Blue crosses represent expression values in MYCN single copy (a)
and surviving patients (b), respectively. Red crosses depict expression values in MYCN-amplified (a) and deceased patients (b), respectively.
Heat map and cluster dendrogram of all significant (p < 0.05) RNAs differentially expressed between MYCN-amplified vs. MYCN single copy
patients and surviving patients vs. deceased, respectively. Note that the MYCN status allows for perfect separation, while the classification
according to survival yields one wrongly assigned sample. Clustering was based on Canberra distance and single-linkage clustering.
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downregulated gene (Table 1, see Methods), implying that
these genes are also bonafide direct MYCN targets. In total,
32% of the upregulated and 37% of the downregulated genes
could be verified as either known MYCN targets or novel tar-
gets containing E-boxes. We first validated upregulation of
the top-ranked target genes hexokinase 2 (HK2) and BZW2
in the SH-EP MYCN-ER model system as well as in a SH-EP
subclone, designated WAC2, which is engineered to stably
overexpress MYCN.21 Upregulation of HK2 as well as BZW2
mRNA by real-time PCR could be seen in both of the
in vitro systems with forced expression of MYCN. HK2 and
BZW2 expression were also found to correlate with MYCN
amplification in an independent cohort of 113 neuroblastoma
patients profiled by Affymetrix HuEXST1.0 arrays (Schramm
et al., submitted, Figs. 4c and 4e). Taken together, reanalyses
of microarray data from primary NB confirmed that HK2,
BZW2 and RPTOR are significantly correlated with MYCN
amplification (Supporting Information Fig. 2). These data
exemplify that the MYCN targets identified here by sequenc-
ing can also be validated by independent methods. We next
Figure 4. Significantly differentially expressed genes between MYCN-amplified tumors and MYCN normal tumors verified in an in vitro NB
model with inducible MYCN expression. Data are presented as strip charts of normalized read count as pairwise comparison of genes that
are upregulated upon MYCN induction in vitro (a) and positively correlated with MYCN amplification in vivo (b). Blue color depicts data
from the NB in vitro system without MYCN induction (a) or from MYCN normal tumors (b). Red color depicts data from the NB in vitro
system with MYCN induction (a) or from tumors with MYCN amplification (b). The top target genes HK2 and BZW2 are upregulated in
MYCN-amplified tumors in an independent cohort of primary NB analyses using exon-level expression analyses (c, e, Schramm et al.,
submitted). Numbers refer to the probe sets for the respective genes on the array. HK2 and BZW2 mRNA are also upregulated in two in
vitro NB models, upon overexpression or induction of MYCN, respectively (d, f). Displayed are the fold changes of normalized HK2 and
BZW2 mRNA expression measured by semi-quantitative RT-PCR in MYCN-overexpressing WAC2 cells compared to the parental cell line SH-
EP and in SH-EP MYCN-ER cells following MYCN activation (SH-EP MYCNþ) compared to cells without induction of MYCN (SH-EP MYCN).
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focused on classification of MYCN targets genes to better
understand the molecular processes regulated by MYCN in
neuroblastoma. For these purpose, we looked into GO and
KEGG databases to identify pathways significantly associated
with MYCN. Analyses of over-representation of genes within
a pathway indicated that MYCN significantly modulated
genes involved in protein biosynthesis and the mTOR path-
way. GO analyses revealed that genes coding for ribosomal
subunits, as well as genes involved in ‘‘ribonucleoprotein
complexes’’ were significantly enriched and upregulated both
in vitro and in vivo by MYCN (Fig. 5a, p value <0.001).
KEGG pathway analyses confirmed this association and
implied that three genes of the mTOR pathway, REDD1/
DDIT4, 4EBP1 and RPTOR, were significantly altered by the
MYCN status in vivo and in vitro (Fig. 5b and Supporting In-
formation Table 2, adjusted p value: 8  104). A significant
correlation between RPTOR expression and MYCN amplifica-
tion could also be seen in an independent panel of primary
neuroblastoma (Supporting Information Fig. 2). We therefore
decided to look for mTOR pathway activation in a model of
MYCN-driven neuroblastoma, the TH-MYCN mouse.29 In
this model system, we used phosphorylation of the S70 kinase
and AKT as a readout of AKT/mTOR activation in the
MYCN-driven tumors. Indeed, we could demonstrate tumor-
specific activation of the mTOR pathway in tumors obtained
from TH-MYCN mice compared to normal tissue from the
same mice (Fig. 5c). To test, whether upregulation of mTOR
pathway genes was concomitant with sensitivity to mTOR in-
hibition, we performed in vitro proliferation assays using the
mTOR inhibitor BEZ-235, which is currently in late phase of
clinical development. Sensitivity to BEZ-235 was comparable
between SH-EP and WAC2 cells and even more pronounced
in SH-EP MYCN-ER cells upon MYCN activation (Fig. 5d,
SH-EP MYCNþ).Thus, we could link two cancer-relevant
pathways, protein biosynthesis and the mTOR pathway to the
MYCN status in neuroblastoma by using transcriptome NGS.
Discussion
Deciphering cancer genomes and transcriptomes is estimated to
yield a wealth of information, which can be exploited for model-
ing tumorigenesis as well as for setting up individualized treat-
ment of cancer patients. Reports available so far have established
a correlation between mutational frequency in cancer, patient
age and exposition to potentially carcinogenic agents such as
UV-light or smoking. This complicates the hunt for the driving
mutational events given a high background of acquired passen-
ger mutations. Moreover, intratumoral heterogeneity could fur-
ther complicate the design of rationale, individualized treatment
options.30 In those childhood tumors, for which entire genomes
have been sequenced, such as medulloblastoma,31 retinoblas-
toma32 and neuroblastoma,6 patients have significantly lower
numbers of mutations compared to adult tumors. This should
in principle facilitate the search for the tumor driving events, at
least for the sporadic forms of the disease. Still, the route from
the tumor genome to the tumor phenotype demands analyses of
the intermediate steps including alterations in the tumor tran-
scriptome. RNA profiles can be expected not only to include sig-
natures but also to give valuable hints on aberrantly activated
signaling pathways in tumors, which can be used for targeted
therapies. As a first step toward this direction, we here describe
for the first time the entire transcriptome of 20 primary NB
using next-generation sequencing. Because we previously
described the non-coding transcriptome of NB,16 we here
focused on protein-coding transcripts and identified genes and
patterns associated with the most aggressive NB subtype, charac-
terized by amplification of the MYCN oncogene. As expected,
mRNA was identified as the predominant RNA species follow-
ing annotation of sequences obtained by RNA-NGS, but we
could also detect a considerable amount of snoRNAs, whose
function is presently poorly understood. Previous reports have
also linked expression of ncRNAs/snoRNAs as well as miRNAs
to MYCN amplification19,33 and it was shown that MYCN
expression itself is controlled by miRNAs.34 It is speculated that
ncRNAs can function in regulating gene expression, which is
also of functional importance in developmental processes as well
as in cancer progression.35–37 Thus, the noncoding part of the
transcribed regions of the genome can be expected to harbor an
additional layer of regulation to gene expression in addition to
miRNAs in neuroblastoma and other tumors.
Analyses of the most divergently expressed transcripts
between MYCN-amplified and MYCN-single copy tumors
confirmed the principled differences between these two
groups, which has also been pointed out before.38,39 Hier-
archical clustering using these differentially expressed tran-
scripts as input revealed a perfect separation of patients with
and without MYCN amplification, emphasizing the homoge-
neity of discriminative patterns (Fig. 3c).
Although the sequencing depth achieved in our approach
was not sufficient to cope with alternative transcript use, we
Table 1. Intersection of MYCN targets identified both in vitro and in
vivo
Database/Motif
Upregulated
MYCN targets
Downregulated
MYCN targets
MYCNot HK2 ITM2C
CD44
MycDB U5-RNA MEIS1
SCML2 LAMP2
HK2 GABARAP
SERPINB1
TMSB4X
E-Box overrepresented
in promoter
SNORA76 (CACGTG) CD44 (CATGTG)
SNORD6 (CATGTG)
SNORD77 (CATTTG)
PTCH2 (CATTTG)
SCML2 (CATCTG)
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were able to identify differentially expressed transcripts asso-
ciated with MYCN in vivo and regulated by MYCN in vitro
in a NB model system with inducible MYCN (Fig. 4). The
most prominently regulated target, HK2, was validated both
in an independent cohort of primary neuroblastomas as well
as in an NB in vitro model with inducible nuclear MYCN
translocation, SH-EP MYCN-ER. Induction of HK2 as well as
other targets of the glycolytic pathway has been recently asso-
ciated with the MYCN-mediated Warburg effect in
neuroblastoma.40 Functional significance of other targets,
especially the snoRNAs, which are upregulated both in vitro
and in vivo by MYCN remains to be determined.
Analyses of associated pathways using GO and KEGG
databases linked protein biosynthesis and the mTOR path-
way to MYCN-upregulated genes in NB and these were also
positively correlated with MYCN amplification in primary
tumors. Protein biosynthesis has also been reported to be
induced by MYCN in vitro before in an unbiased approach
using SAGE technology41 and this was verified in this study
also for primary tumors. In a previous array based study,
Figure 5. (a) Gene ontology (GO) analyses revealed a significant association of genes upregulated in tumors from patients with MYCN
amplification with GO terms for protein biosynthesis (marked in dark grey). (b) KEGG pathway analyses returns a significant association of
genes upregulated in tumors from patients with MYCN amplification with the mTOR pathway (genes marked in dark grey are upregulated in
MYCN-amplified tumors). (c) Activation of Akt/mTOR pathway is seen in tumors (tu) from MYCN-driven murine neuroblastoma but not in
control tissue (liver ¼ li). (d) Sensitivity to mTOR pathway inhibition using BEZ-235 is high in neuroblastoma cells and comparable between
parental SH-EP cells (open squares, IC50 ¼ 29 nM) compared to those with enforced expression (WAC2, open circles, IC50 ¼ 28 nM) with
slightly increased sensitivity upon activation of MYCN (SH-EP MYCNþ, open triangles, IC50 ¼ 12 nM).
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cell cycle genes and genes involved in kinetochore assembly
had been associated with survival and MYCN amplification
in primary NB, but these genes have not been verified using
NB in vitro models.42 By contrast, we found three genes
from the mTOR pathway to be upregulated by MYCN,
which strongly supports the notion that the mTOR/PI3K/
Akt axis is an important feature of MYCN-driven survival
capabilities of tumor cells. It could also been shown that in-
terference with this pathway in turn leads to the degrada-
tion of MYCN protein in neuroblastoma using small mole-
cule inhibitors of mTOR such as rapamycin or novel drugs
such as BEZ-235 currently in clinical development.43,44 We
here demonstrated tumor-specific activation of the mTOR
pathway in a MYCN-driven neuroblastoma mouse model.
Furthermore, we confirmed that neuroblastoma cells are
sensitive toward mTOR-directed treatment, in line with a
previous report demonstrating MYCN downregulation in
neuroblastoma cells upon mTOR inhibition.43 Here, we
show that especially in cells with overexpression or activa-
tion of MYCN mTOR inhibition might be appropriate to
effectively block proliferation.
Taken together, we provide first insights into the tran-
scriptomal landscape of MYCN-amplified neuroblastoma
using next-generation RNA sequencing. We have identified
genes and pathways including coding mRNAs as well as
noncoding RNAs associated with MYCN in vivo and in vitro.
Our results strongly argue in favor of further evaluation of
mTOR inhibitors for the treatment of MYCN-amplified NB.
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